Ustekinumab as Induction and Maintenance Therapy for Crohn’s Disease
Western University · Robarts Clinical Trials · +18 more institutions
Indexed incrossref
Abstract
Ustekinumab, a monoclonal antibody to the p40 subunit of interleukin-12 and interleukin-23, was evaluated as an intravenous induction therapy in two populations with moderately to severely active Crohn's disease. Ustekinumab was also evaluated as subcutaneous maintenance therapy.
Citation impact
1,787
total citations
- FWCI
- 141.91
- Percentile
- 100%
- References
- 16
Citations per year
Authors
27- BGBrian G. FeaganCorresponding
Western University, Robarts Clinical Trials
- WJWilliam J. Sandborn
Western University, University of California San Diego, Robarts Clinical Trials
- CGChristopher Gasink
Western University, Robarts Clinical Trials, Janssen (Switzerland)
- DJDouglas Jacobstein
Western University, Robarts Clinical Trials, Janssen (Switzerland)
- YLYinghua Lang
Western University, Robarts Clinical Trials, Janssen (Switzerland)
Topics & keywords
Topics
Keywords
- Ustekinumab
- Medicine
- Crohn's disease
- Maintenance therapy
- Interleukin 23
- Monoclonal antibody
- Monoclonal
- Disease
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.